Slideflow Labs is enhancing its cloud-based cancer diagnostic platform, Slideflow Pro, to improve pathology analysis and biomarker development.
Slideflow Labs, an AI pathology company originating from the University of Chicago, is expanding the use of its Slideflow Pro platform, which analyzes digitized pathology slides. This platform aims to facilitate the creation of AI-driven biomarkers that can address critical questions in cancer care. Notably, research published in *Nature Cancer* highlights the potential of deep learning algorithms to predict genomic alterations and molecular subtypes directly from tumor biopsy slides.
The modular and scalable design of Slideflow Pro allows it to be integrated into various healthcare settings, accommodating different hardware configurations for scanning and analyzing slides in near real-time. This accessibility is intended to empower institutions that may lack extensive digital pathology frameworks or machine-learning expertise, promoting broader use of AI in clinical environments.
Currently focusing on breast cancer, the platform aims to predict molecular subtypes and recurrence risks, assisting clinicians in making informed treatment decisions. Recent accolades, including recognition from the Northwestern Medicine and Techstars Healthcare Accelerator and a substantial prize at the University of Chicago’s New Venture Challenge, underscore the company’s momentum. As Slideflow Labs works towards regulatory validation and quality control, it is poised to make significant advancements in personalized cancer diagnostics.